PT  - JOURNAL ARTICLE
AU  - M Piazza
AU  - R Orlando
AU  - G Tosone
AU  - D Tiseo
AU  - M C Conte
AU  - F Minervini
AU  - G Santoro
AU  - F Scordino
AU  - D Vitale
TI  - Treatment of chronic hepatitis C with recombinant interferon alfa-2b.
AID  - 10.1136/gut.34.2_Suppl.S128
DP  - 1993 Jan 01
TA  - Gut
PG  - S128--S129
VI  - 34
IP  - 2 Suppl
4099  - http://gut.bmj.com/content/34/2_Suppl/S128.short
4100  - http://gut.bmj.com/content/34/2_Suppl/S128.full
SO  - Gut1993 Jan 01; 34
AB  - In a study of 87 patients with chronic hepatitis C, 12 months' treatment with interferon alfa-2b at a dose of 6 million units (MU) three times per week seemed to be more effective than treatment with 3 MU three times a week for two months plus 1.5 MU three times a week for 10 months in increasing the percentage of long term responders. The percentage of patients in whom alanine amino-transferase activities returned to normal was highest in the 6 MU group, as was the percentage of responders who sustained this normal activity after treatment. Side effects were moderate and self-limited in most patients.